NCI initiates trial for preoperative radiation therapy in recurrent abdominal adrenocortical carcinoma
The National Cancer Institute is testing a new external beam radiation therapy before surgery in patients with resectable recurrent adrenocortical carcinoma.
Phase III
National Cancer Institute
Status
Active
Sponsor
Oncology-focused pharma companies
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of this trial by the NCI is significant as it explores a novel preoperative treatment for a rare cancer, which could reshape clinical practices and competitive strategies in oncology. Success in this trial may establish new standards of care, influencing treatment options and market dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial enrollment rates, interim results, and overall survival outcomes post-surgery.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.